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Abstract
Response adaptive randomization is appealing in confirmatory adaptive clinical trials
from statistical, ethical, and pragmatic perspectives, in the sense that subjects are more likely
to be randomized to better performing treatment groups based on accumulating data. The
Doubly Adaptive Biased Coin Design (DBCD) is a popular solution due to its asymptotic
normal property of final allocations, which further justifies its asymptotic type I error rate
control. As an alternative, we propose a Response Adaptive Block Randomization (RABR)
design with pre-specified randomization ratios for the control and high-performing groups
to robustly achieve desired final sample size per group under different underlying responses,
which is usually required in industry-sponsored clinical studies. We show that the usual test
statistic has a controlled type I error rate. Our simulations further highlight the advantages of
the proposed design over the DBCD in terms of consistently achieving final sample alloca-
tions and of power performance. We further apply this design to a Phase III study evaluating
∗This work was supported by AbbVie Inc. AbbVie participated in the interpretation of data, writing, review,
and approval of the content of this work. Tianyu Zhan, Ziqian Geng, Lanju Zhang, Yihua Gu, Ivan S.F. Chan are
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the efficacy of two dosing regimens of adjunctive everolimus in treating tuberous sclerosis
complex but with no previous dose-finding studies in this indication.
Keywords: Confirmatory adaptive design; Sample size; Type I error control; Unweighted statis-
tics
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1 Introduction
Randomized clinical trials (RCTs) remain the gold standard for understanding the effect of a
treatment or other intervention relative to placebo or standard of care (Diamond et al., 2015; Wu
et al., 2017; Barnhart et al., 2018). To make the trial more efficient and ethical, confirmatory
adaptive designs become more widely acceptable and popular to allow flexible interim modifi-
cations in the ongoing trials using unblinded data without compromising the type I error rate
(Bauer et al., 2016). An appealing branch of adaptive designs is the so-called response adaptive
randomization (RAR). It is an adaptive feature in which the chance of a newly enrolled sub-
ject being assigned to a treatment arm varies over the course of the trial based on accumulating
outcome data for subjects previously enrolled (FDA, 2018). Statistical, ethical, and pragmatic
rationales are supporting the advantage of using RAR as more subjects are being assigned to the
more promising treatment arms.
The idea of adaptive randomization could be traced back to the play-the-winner rule (Zelen,
1969), and its generalization to handle delayed responses (Wei, 1979). Doubly Adaptive Biased
Coin Design (DBCD) was further proposed to account for both the current sample proportion and
a desired allocation function (Eisele, 1994; Eisele and Woodroofe, 1995; Hu and Rosenberger,
2003; Hu and Zhang, 2004; Tymofyeyev et al., 2007). Strong consistency and asymptotic normal-
ity are established for the sample proportion to each treatment arm (Hu and Rosenberger, 2006).
Since DBCD leans toward a fixed target allocation when the sample size is large enough; then
the type I error rate of using conventional statistical test in pairwise comparison is asymptotically
controlled at a desired level α.
Certain treatment responses need to be assumed for DBCD to achieve a desired final sample
size for placebo and the selected treatment group, which is usually required in industry-sponsored
clinical studies due to efficiency considerations and regulatory requirement. However, the final
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sample size maybe different from the target if the observed data deviate. This is more challenging
when there is no available prior knowledge on the efficacy profile of treatment regimes, as with
the case study we considered at Section 6.
To facilitate the application of response adaptive randomization in clinical trials, Wang and
Cui (2007) proposed a framework with pre-defined randomization ratios for the control and high-
performing groups to address the dose selection issue in a seamless Phase II/III trial. Motivated
by their work, we propose a Response Adaptive Block Randomization (RABR) design, where
subjects are adaptively randomized to different treatment groups based on the order of their stan-
dardized effect sizes and a pre-specified block randomization vector. As can be seen later on from
the simulation studies at Section 5, our RABR is more robust than DBCD in achieving a desired
final sample size per group under varying underlying responses. The built-in block randomiza-
tion feature of RABR not only protects potential unstable randomization in small-size-trials, but
also facilitates the implementation of our design in practice, in the sense that IRT (Interactive
Response Technology) schedules could be specified in advance.
Moreover, we prove that the one-sided type I error rate for pairwise comparisons is analyt-
ically controlled at a nominal level by using usual test statistics in our proposed RABR design.
A similar phenomenon was observed by the promising zone approach in the context of a group
sequential trial, where the type I error rate is not inflated if one increases sample size with promis-
ing unblinded interim results (Chen et al., 2004). In contrary to the weighted analysis approaches
where test statistics are combined from an independent cohort of subjects (Cui et al., 1997, 1999),
our proposed RABR design could adjust the randomization ratios sequentially for each subject
being enrolled. Multiplicity issues among treatment groups are further handled by existing mul-
tiple testing procedures, for example the step-down Dunnett (Dunnett and Tamhane, 1991) or
Bonferroni procedure, to control familywise error rate (FWER) in the strong sense (Bretz et al.,
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2016).
The remainder of this article is organized as follows. In Section 2, we review the Doubly
Adaptive Biased Coin Designs (DBCD) with a continuous endpoint. In Section 3, we introduce
our proposed Response Adaptive Block Randomization Design (RABR). The analytic type I error
protection in pairwise comparison is proved in Section 4. Simulations are performed to evaluate
type I error and power under various scenarios in Section 5. We further re-design a confirmatory
trial for treating tuberous sclerosis complex with RABR at Section 6. Concluding remarks are
provided in Section 7.
2 Review of the Doubly Adaptive Biased Coin Designs
In this section, we review the Doubly Adaptive Biased Coin Designs (DBCD) proposed by Hu
and Zhang (2004). Let us consider a clinical trial with a continuous endpoint, where the response
Xgi for subject i in treatment group g follows independent normal distribution with known com-
mon variance,
Xgi ∼ N (µg, σ2), (1)
for g = 0 labeling placebo and g = 1, . . . ,m for m treatment groups. We assume that a larger
response is favorable, and the response of each subject is observed right after its enrollment in
the study.
After a burn-in period where M subjects have been equally randomized to m+ 1 groups, the
study adjusts the randomization probability to each treatment group g (g = 0, 1, . . . ,m) based on
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the following allocation function:
ag(η, 0, τg) = 1, ag(η, 1, τg) = 0,
ag(η, θg, τg) =
®
τg
Ç
τg
θg
åη´/ m∑
j=0
τj
Ç
τj
θj
åη , (2)
where η is a non-negative tuning parameter controlling randomness of randomization probabil-
ities. The asymptotic allocation variance is a monotone decreasing function of η, and usually
η = 2 is chosen in practice (Hu and Zhang, 2004). In ag(η, θg, τg), θg is the proportion of sub-
jects that have been randomized to group g so far, and τg is the targeting allocation probability
for group g. In this article, we consider τg in the following form:
τg =
[®
Φ
Ç
µg − λ
σ
å´1/2]/ m∑
j=0
®
Φ
Ç
µj − λ
σ
å´1/2 , (3)
which is a direct generalization of the allocation function with a continuous endpoint in two-
group comparison (Biswas and Mandal, 2004) to a study with multiple treatment groups. The
tuning parameter λ needs to be pre-specified.
We further use “τg to denote an estimate of τg by replacing µg with the sample mean in group
g. At each interim checkpoint, the adaptive randomization probability for treatment group g is
ag(η, θg, “τg). Under certain regulatory conditions, it can be shown that “τg and θg converge to τg
almost surely, and with an asymptotic bivariate normal distribution (Hu and Zhang, 2004). When
the sample size is large enough, the study reaches stabilized randomization probabilities to each
group g at τg. Therefore, asymptotically, any level α test for a non-adaptive design is also valid
to control the pairwise comparison error rate at α. One could further use certain multiple test
procedures to control the familywise error rate.
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Challenges exist for this type of design, as it cannot robustly achieve a desired sample size
for the selected arm and placebo under different underlying responses. This problem is further
studied in Section 5. Moreover, block randomization is not available given the functional form
of ag in (2). The trial might end up with an undesired final proportion per group, especially when
the total sample size is relatively small. In the next section, we introduce our proposed Response
Adaptive Block Randomization Design as an alternative option along with an analytic type I error
protection.
3 Response Adaptive Block Randomization Design
As a starting point, let us consider a simple two-stage study design with one interim adaptation
on the randomization. In stage 1, there are ng1 subjects that have been recruited to group g with
sample mean X
g
1 =
∑ng1
i=1X
g
i /n
g
1, for g = 0, 1, . . . ,m. Further denote X
g
1 = (X
g
1 , . . . , X
g
ng1
)
as the vector of responses in group g at stage 1. Similar to the DBCD as described in Section
2, we utilize stage 1 as a burn-in period, where equal randomization is adopted on the placebo
and m treatment group: n01 = n
1
1 = · · · = nm1 . The burn-in size M is equal to
∑m
g=0 n
g
1.
Correspondingly, ng2 andX
g
2 are notations for sample size and sample mean in group g at stage
2. We further useX
0
= (X
0
1n
0
1 +X
0
2n
0
2)/(n
0
1 + n
0
2) and n
0 = n01 + n
0
2 to denote the sample mean
and sample size for the placebo in the whole study.
Having observed the first stage data D1 = (X01 ,X
1
1 , . . . ,X
m
1 ), we adjust the randomization
ratios of m treatment groups in a data-driven manner by assigning more subjects to the more
promising dose(s). Let vector r = (r0, r1, r2, . . . , rm) denote a pre-specified block randomization
vector for our design, where rg are integers satisfying r1 ≥ r2 ≥ · · · ≥ rm for g = 1, . . . ,m.
The block size B is equal to
∑m
g=0 rg. The first element r0 in r specifies the number of subjects
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being randomized to placebo group in one block. Therefore, the randomization probability to the
placebo is fixed at r0/B. The rest of the m elements in r : r1, . . . , rm are assigned to m treatment
groups based on a decreasing order of the standardized response by assuming known variance,
(ng1)
1/2X
g
1/σ, (4)
for g = 1, . . . ,m. That is to say, the group with the largest standardized observed mean in the first
stage gets the largest probability of being randomized in the second stage (r1/B). The functional
form in (4) is appealing as it is on the same scale of the final test statistics, and also eases our
analytic proof of pairwise type I error rate control at Section 4.1. Moreover, as studied in Section
5, it also contributes to the achievement of desired randomization proportions to selected groups.
Even if r is pre-specified, its assignment to each treatment group g, g = 1, . . . ,m is dependent
on the previous stage dataD1.
For demonstration, let’s consider a study with m = 2 active doses with g = 0, 1, 2 denoting
the placebo, the low dose and the high dose group, respectively. Without loss of generality,
we focus on the low dose g = 1 for illustration. We use N12 to denote the random variable
of the sample size in treatment group g = 1 at the second stage. It takes the value β1n02 if
(n11)
1/2 X
1
1/σ ≥ (n21)1/2 X
2
1/σ, but takes the value β2n
0
2 otherwise, where β1 = r1/r0 and
β2 = r2/r0. Essentially, subjects are more likely to be assigned to the low dose in the second
stage if the treatment effect is more promising than that in the high dose based onD1. If β1 = β2;
then it degenerates to a non-adaptive design with equal randomization.
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4 Inference Procedures
4.1 Type I error rate in pairwise comparison for a continuous endpoint
For simplicity, we assume σ = 1 for the rest of this article. To test the null hypothesis H0 :
µ0 ≥ µ1 against the one-sided alternative hypothesis H1 : µ0 < µ1, one could use the following
z statistics S, which is defined by
S =
Ñ
X
1
1n
1
1 +X
1
2N
1
2
n11 +N
1
2
−X0
é/Ç
1
n11 +N
1
2
+
1
n0
å1/2
.
Based on example 8.3.29 in Casella and Berger (2002), it is equivalent to considering only the
boundary point in H0, which is µ0 = µ1. The statistics S can be decomposed by S (N12 , N
1
2 ),
S
Ä
N12 , N
1
2
ä
= {w1(N12 )}1/2Z1 + {1− w1(N12 )}1/2Z2(N12 ), (5)
where
S (a, b) ={w1(b)}1/2Z1 + {1− w1(b)}1/2Z2(a), (6)
Z1 =(n
1
1)
1/2
Å
X
1
1 − µ0
ã
,
Z2(a) =
®
a
n11 + a
Å
X
1
2 − µ0
ã
−
Å
X
0 − µ0
ã´/® a
(n11 + a)
2
+
1
n0
´1/2
,
w1(b) =
n11
(n11 + b)
2
/®
1
n11 + b
+
1
n0
´
, (7)
Following Theorem 1, 2, and Example 2 in Liu et al. (2002), one can show thatZ1 andZ2(N12 )
follow two independent standard normal distributionsN (0, 1) under the null hypothesisH0 (µ0 =
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µ1). Even though N12 depends on D1, the fact that Z2(N
1
2 ) follows the same N (0, 1) given
different realizations of N12 (either β1n
0
2 or β2n
0
2) ensures the marginal independence between Z1
and Z2(N12 ). This property is also referred to as the conditional invariance principle (Brannath et
al., 2007).
In a non-adaptive design, N12 takes a fixed value, say n
1
2. By the normal response assumption
in (1), S (n12, n
1
2) followsN (0, 1) under the null hypothesisH0. Therefore, prH0 [S (n12, n12) > c] =
α, where c = Φ−1(1 − α) and Φ−1(·) is the inverse of the cumulative distribution function of
a standard normal distribution. The probability of erroneously detecting a significant low-dose
treatment effect with no multiplicity adjustment under H0 is exactly equal to a nominal level α,
for example α = 0.025 in practice.
In adaptive design where N12 depends on D1, S (N
1
2 , N
1
2 ) does not follow N (0, 1) due to the
random weight {w1(N12 )}1/2. Proper adjustment is required to protect the type I error rate at α.
A popular approach is to use CHW statistics S (N12 , n
0
2) with a pre-specified weight {w1(n02)}1/2
(Cui et al., 1997, 1999). It can be shown that prH0 [S (N
1
2 , b) > c] = α as long as {w1(b)}1/2 ∈
(0, 1), and is independent from interim adaptation dataD1.
In our proposed design, we still want to utilize the conventional statistics S (N12 , N
1
2 ) in (6)
and the significance cutoff c = Φ−1(1 − α) in our inference procedure. However, the control of
type I error rate requires further investigation. Before studying the one-sided type I error control,
we first prove the following Lemma,
Lemma 1. For any constant c′ ∈ R,Q(w1) = pr
î
(w1)
1/2Z1 + (1− w1)1/2Z2 > c | Z1 ≤ Z3 + c′
ó
is a decreasing function with respect to w1 ∈ (0, 1) for Z1, Z2 and Z3 following mutually inde-
pendent N (0, 1).
The proof is provided in the Supplemental Material Section 1. In the following theorem, we
prove that the probability of falsely detecting treatment effect with the decision rule S (N12 , N
1
2 ) >
10
c in the proposed design under H0 is upper bounded by α.
Theorem 1. In the RABR design with a normal response in (1) and two active treatment groups,
we have
prH0
¶
S
Ä
N12 , N
1
2
ä
> c
© ≤ α. (8)
Proof. The randomization vector r satisfies r1 ≥ r2 ≥ 0, which is equivlent to β1 ≥ β2 ≥ 0
given r0 at each stage. Consider¶
w1(β1n
0
2)− w1
Ä
β2n
0
2
ä©Ç 1
n11 + β1n
0
2
+
1
n0
åÇ
1
n11 + β2n
0
2
+
1
n0
å
=
n11
(n11 + β1n
0
2)
2(n11 + β2n
0
2)
− n
1
1
(n11 + β2n
0
2)
2(n11 + β1n
0
2)
+ (9)
n11
(n11 + β1n
0
2)
2n0
− n
1
1
(n11 + β2n
0
2)
2n0
. (10)
Given that β1 ≥ β2 ≥ 0, one could verify that (9)≤ 0, (10)≤ 0, and therefore w1(β1n02) ≤
w1 (β2n
0
2).
Based on the decomposition of S (N12 , N
1
2 ) in (5), Z1 and Z2(N
1
2 ) follow two independent
N (0, 1)’s under null H0. We drop (N12 ) in notation of Z2(N12 ) for simplicity. Under H0, we have
prH0
¶
S
Ä
N12 , N
1
2
ä
> c
©
=prH0
î{w1(β1n02)}1/2Z1 + {1− w1(β1n02)}1/2Z2 > c | Z1 ≥ Z21 + c′ó pr ÄZ1 ≥ Z21 + c′ä+
prH0
î{w1(β2n02)}1/2Z1 + {1− w1(β2n02)}1/2Z2 > c | Z1 < Z21 + c′ó pr ÄZ1 < Z21 + c′ä ,
(11)
where Z21 = (n
2
1)
1/2 (X
2
1−µ0), c′ = (n21)1/2µ0− (n11)1/2µ0. Note that the condition Z1 ≥ Z21 + c′
is equivalent to our arm selection criteria if treatment group 1 is more promising, as defined by
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the evaluation function (4). On the other hand, consider a CHW statistic with a fixed weight
{w1(β1n02)}1/2 for example, we have an analytically type I error control at α :
α =pr
¶
S
Ä
N12 , β1n
0
2
ä
> c
©
=pr
î{w1(β1n02)}1/2Z1 + {1− w1(β1n02)}1/2Z2 > có
=pr
î{w1(β1n02)}1/2Z1 + {1− w1(β1n02)}1/2Z2 > c | Z1 ≥ Z21 + c′ó pr ÄZ1 ≥ Z21 + c′ä+
pr
î{w1(β1n02)}1/2Z1 + {1− w1(β1n02)}1/2Z2 > c | Z1 < Z21 + c′ó pr ÄZ1 < Z21 + c′ä (12)
From Lemma 1 and w1(β1n02) ≤ w1 (β2n02) shown previously, we have
pr
î{w1(β2n02)}1/2Z1 + {1− w1(β2n02)}1/2Z2 > c | Z1 < Z21 + c′ó
≤pr î{w1(β1n02)}1/2Z1 + {1− w1(β1n02)}1/2Z2 > c | Z1 < Z21 + c′ó ,
and therefore (11) ≤ (12). Theorem 1 is proved.
Next we generalize Theorem 1 from a single adaptation to one with multiple checkpoints in
the following Theorem:
Theorem 2. In the RABR design with a normal response in (1), two active treatment groups and
more than two adaptation timepoints, we have
prH0
¶
S
Ä
N12 , N
1
2
ä
> c
© ≤ α. (13)
The proof follows by iteratively applying Theorem 1 using backward induction from the last
two stages to early stages. The idea is based on Brannath et al. (2002), who prove that the
type I error is equal to the nominal level α in an adaptive design with multiple stages by using
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fixed weight in (7). Theorem 1 and 2 could be straightforwardly generalized to accommodate
a study with three active treatment groups, with proof in the Supplemental Material Section 2.
The generalization to m > 3 active treatment arms needs to be cautious, as the analytic proof
of type I error protection needs additional conditions on the study design. More discussion on
this generalization could be found in Section 7. In the Section 3 of Supplemental Material, we
provide the corresponding proof of using a proportional test in the context of a binary endpoint.
The proof of error rate protection in pairwise comparison could be generalized to other in-
tersection hypotheses as well. Therefore, by applying proper multiple testing procedures, for
example the single-step Dunnett test (Dunnett, 1955) based on the closure principle (Marcus et
al., 1976), it is sufficient to protect the one-sided familywise error rate at α in the strong sense.
5 Simulation studies
By simulations, we study the type I error rate of RABR design with a continuous endpoint at
Section 5.1. The final allocations and power are further compared with DBCD at Section 5.2
under several response assumptions.
Consider a clinical trial with three active treatment dosing groups, D1, D2, D3, and a placebo.
There are M = 60 subjects being recruited in the burn-in period with fixed equal randomization
probabilities and a subsequent 60 subjects being adaptively and sequentially randomized. There-
fore, there are 61 stages including the burn-in period with a total sample size of n = 120. At
the final efficacy analysis stage, the dosing group with the smallest step-down Dunnett adjusted
p-value is chosen as the selected one. Its efficacy is further confirmed if its adjusted p-value is
smaller than α. We use S1 to denote the selected treatment group, and use S2 and S3 for the
second best and worst groups.
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The study objective is to identify and confirm the efficacy of the best performing dose S1 with
one-sided FWER controlled at α = 0.025, while achieving a desired final sample size for that
group and the placebo. Note that the choice of S1 from D1, D2 and D3 depends on the data, and
dose not necessarily correspond to a particular dosing group.
5.1 Type I error control
To evaluate the type I error rate of using the usual z statistics in RABR, we set the response mean
for all groups to be the same, that is µg = µ0 for g = 0, 1, 2, 3, where µ0 is considered at 0 and
1. The known variance σ2 is assumed to be 1. The following 5 different adaptive randomization
ratio vectors r’s are considered:
1. rA = (8, 4, 4, 4),
2. rB = (8, 5, 4, 3),
3. rC = (8, 7, 4, 1),
4. rD = (8, 5, 5, 2),
5. rE = (9, 9, 1, 1).
For example in rB, the randomization probability to placebo is fixed at 8/20 in the RAR pe-
riod, while the best performing dose gets 5/20. The first rA corresponds to a non-adaptive design
with fixed equal randomization probability to each treatment group. Its analytic pairwise com-
parison error rate at 0.025 serves as a benchmark to characterize the randomness of simulations.
The number of simulation iterations is 100, 000. We also consider a small size trial with a total
of n = 40 subjects and burn-in size of M = 20.
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As can be seen from Table 1, the probability of erroneously claiming a significant treatment
effect with no multiplicity adjustment in each dose is controlled at α = 0.025 for all scenarios
evaluated. With step-down Dunnett procedure to adjust multiplicity, the adjusted error rate for
each dose is much smaller than α, while the overall FWER is controlled at α.
5.2 Power and final allocations
Next we evaluate the power and final allocations of our RABR against DBCD under several
alternative hypotheses. Given a total sample size of n = 120, let’s consider a study with a target
sample size for the placebo and the selected dose at 42, which corresponds to 35% of the total
sample size.
For our proposed RABR, given that M = 60 in the burn-in period, one could utilize the
adaptive randomization vector rE = (9, 9, 1, 1) to achieve this. Note that in order to exactly
reach the desired size, the best performing group identified based on the burn-in period should
consistently receive a 9/20 randomization probability throughout the RAR process. As shown
later on, our RABR leans toward the desired allocations because the probability of flipping is
relatively small.
When it comes to DBCD, however, one needs to assume a certain response vector µ =
(µ0, µ1, µ2, µ3), and fine tune the parameter λ in (3) to meet the study objective that both the
placebo and the selected arm have a 35% final sample size proportion. Since the response mean
in the placebo is usually different from that in treatment groups, equation (3) requires further ad-
justment. Even with a modified allocation function, the choices of hyper-parameters are sensitive
to the assumed µ, which could lead the study to undesired allocations if observed data deviate.
The function form in (3) is used for demonstration.
Suppose that the study team considers the following three assumptions:
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1. µA = (0.43, 0.68, 0.93, 1.2),
2. µB = (0.43, 1, 1.15, 1.2),
3. µC = (0.43, 1, 1.2, 1.2),
which correspond to a linear, a plateau, and an extreme case where two doses have the same
treatment effect.
Table 2 summarizes the multiplicity adjusted power in the selected arm in RABR, a non-
adaptive design with equal randomization probabilities, and DBCD with λ = −2, 0, 2. The
overall multiplicity adjusted power is the probability of rejecting at least one elementary null
hypothesis, or equivalently rejecting the null hypothesis in the best performing group S1. For
each individual group D1, D2 and D3, we report the probability of selecting this group (if its
adjusted p-value is the smallest among three doses) and confirming its efficacy (if its adjusted
p-value is smaller than α). Therefore, the sum of them from three groups is equal to the overall
power. Our RABR has the largest overall power gain in the linear response µA compared to a
non-adaptive design (83.63% versus 75.61%) and DBCD (83.63% versus 76.00%). It also has
the highest probability of identifying the right dose D3 and confirming its efficacy at 70.26%,
compared to 65.35% in a non-adaptive design and 66.75% in DBCD with λ = 2. The power gain
is due to the fact that RABR increases the sample size in placebo and the selected arm S1 to 42
but decreases those in the two worst performing groups to 18. In µB and µC where the response
means in the last two doses are close or equal, our method also has moderate overall power gain
of claiming significance in the right treatment group (Table 2).
Average sample sizes for selected treatment groups are presented at Table 3. Across all three
underlying response µ’s, RABR robustly reaches the final desired sample size for the placebo,
S1, S2 and S3 at 42, 42, 18 and 18, respectively. For example, under the linear response µA, the
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placebo and S1 receive sizes of 42.01 and 40.69. However, DBCD’s performance is sensitive to
different choices of µ, and could not assign 35% to both placebo and S1. Figure 1 demonstrates
the sample proportion of RABR and DBCD with λ = 2 at each of the 60 RAR checkpoints after
burn-in period. The final observed proportions are reported in the text on the right to each sub-
plot, while the targets are projected by the horizontal dashed lines. Starting from an equal sample
proportion of 25% right after the burn-in period, our RABR accurately and robustly reaches the
desired treatment group allocations under all three µ’s.
6 A case study
Examining Everolimus in a Study of Tuberous Sclerosis Complex (EXIST-3) evaluated two dos-
ing regimens of adjunctive everolimus compared with placebo for treatment-resistant focal-onset
seizures in tuberous sclerosis complex (French et al., 2016). In this phase 3, randomised, double-
blinded, placebo-controlled study, 366 eligible patients were equally and randomly assigned
(1:1:1) to receive placebo, 3-7 ng/mL everolimus (low exposure) and 9-15 ng/mL (high expo-
sure) everolimus with block randomization (block size of six). The primary endpoint was the
proportion of patients achieving at least 50% reduction in seizure frequency during a 12-week
maintenance period, and therefore a larger proportion corresponds to a better outcome. A Bon-
ferroni procedure was used to ensure an one-sided FWER at 2.5%.
In the absence of previous dose-finding studies in this indication, the pre-planned sample size
of 345 patients (115 per group) was determined to provide at least 90% power to detect a differ-
ence in response rate from 15% on placebo to 35% in each of the two everolimus treatment groups
based on a literature review (French et al., 2016). With limited prior knowledge to distinguish the
efficacy of two treatment groups, equal randomization is a reasonable choice for this type of non-
17
Figure 1: Final sample proportions for RABR and DBCD with λ = 2
18
adaptive confirmatory trial. After completing this study, the results revealed that the response
rate was 15.1% with placebo compared with 28.2% (p = 0.0077) for low exposure everolimus
and 40.0% (p < 0.0001) for high-exposure by using Cochran-Mantel-Haenszel Chi-square tests
stratified by four age subgroups. More subjects could have been recruited to the high-exposure
group due to a better efficacy profile and ethical reasons. In the remaining of this section, we re-
design this non-adaptive design with fixed randomization probabilities by our proposed RABR
to assign more subjects to the better performing treatment group.
For demonstration purposes, we reduce the total sample size from n = 345 to 180 to avoid an
over-powered study, and simulate the trial with instant response based on the above underlying
response rates with no stratification factor. Suppose that the target sample size for the placebo
and the selected arm S1 is 72. With a burn-in size M = 90, our RABR could reach the desired
allocations using an adaptive randomization vector r = (7, 7, 1). By adjusting r, one could
achieve a wide range of final allocations. In DBCD, we consider a generalization of the Neyman
allocation as the target allocation function,»
qg(1− qg)∑2
j=0
»
qj(1− qj) ,
where q0 denotes the response rate in the placebo group and g1 and g2 for the two treatment
arms. In all three methods considered (fixed randomization design, RABR and DBCD), the test
of proportion is conducted on the pairwise comparison of each exposure group versus placebo.
Bonferroni procedure is used to adjust multiplicity.
We first study the type I error rate when using the unweighted proportion test under our
RABR design, which is proved to be asymptotically upper bounded by α in the Supplemental
Material Section 3. Based on simulations with 100, 000 iterations, the one-sided error rate for
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Figure 2: Type I error rate for pairwise comparisons and Bonferroni procedure in RABR
each of the two pairwise comparisons is lower than α = 0.025 under a comprehensive scan of
the null response rate. The probability of rejecting at least one elementary null hypothesis by the
Bonferroni procedure is also upper bounded by α (Figure 2).
Next we evaluate power and operating characteristics of the three methods in Table 4. Our
RABR has the highest overall power at 81.58%, compared to the non-adaptive design at 76.09%
and DBCD at 75.06% (Table 4). The probability of selecting and confirming the efficacy of the
right dose (high exposure group) is also the largest (74.59%). Moreover, RABR achieves the
sample size for the placebo and S1 at 72.2 and 70.15, which are close to our target at 72. On the
other hand, it adaptively decreases the sample size in the worst performing treatment group to
37.84.
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7 Concluding remarks
In this manuscript, we propose a practical Response Adaptive Block Randomization (RABR)
design to adaptively assign more subjects to the promising treatment groups based on accumu-
lating interim data. Simulation studies show that, in contrast to DBCD, our RABR robustly and
accurately achieves the target allocations for the placebo and the selected treatment groups under
varying underlying responses. This property, which is usually required in industry-sponsored
clinical trials, makes our RABR more appealing in practice. The built-in block randomization
feature eases the implementation of the IRT system and also contributes to a more stabilized
final allocation. Moreover, we prove that the one-sided type I error rate from pairwise compari-
son of using conventional unweighted statistics in RABR is analytically controlled at a nominal
level α, which facilitates its application in confirmatory clinical trials, where FWER needs to be
strongly controlled. Moderate multiplicity adjusted power gain is available not only in detecting
at least one treatment group, but also in identifying and confirming the most efficacious dosing
group. Our RABR provides an alternative solution to inferentially seamless Phase II/III design
by integrating the identification and confirmation of treatment strategies into one single study.
Note that the generalization of Theorem 1 to m > 3 active treatment arms needs to be cau-
tious, as the condition r1 ≥ r2 ≥ ... ≥ rm ≥ 0 is not sufficient. Numerical calculation is required
to evaluate the multivariate integral, which is beyond the scope of this manuscript. As a compro-
mise, one could enforce another set of constraints on the study design to guarantee an analytic
type I error protection, for example r3 = ... = rm−1 = 1/(m + 1) and r1 ≥ r2 ≥ rm ≥ 0. That
is to say, the adaptive randomization is only employed on the best two and the worst performing
arms. The other m− 3 arms keep the equal randomization probabilities as in the burn-in period.
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Supplementary material
Supplementary materials include the proof of three active treatment groups and of a binary end-
point, as well as the R code to reproduce simulation studies and the case study.
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Supplemental Materials
1 Proof for Lemma 1
Proof. We first express the objective function Q(w1) as
Q(w1) =pr
î
(w1)
1/2Z1 + (1− w1)1/2Z2 > c | Z1 ≤ Z3 + c′
ó
=
∫ 1
0
∫ Φ[Φ−1(t3)+c′]
0
ñ
1− Φ
®
c− (w1)1/2Φ−1(t1)
(1− w1)1/2
´ô
dt1
/
Φ
{
Φ−1(t3) + c′
}
dt3
=
∫ Φ((w1)1/2c−c′)
0
∫ Φ[Φ−1(t3)+c′]
0
ñ
1− Φ
®
c− (w1)1/2Φ−1(t1)
(1− w1)1/2
´ô
dt1
/
Φ
{
Φ−1(t3) + c′
}
dt3+
∫ 1
Φ((w1)1/2c−c′)
Ç
α−
∫ 1
Φ[Φ−1(t3)+c′]
ñ
1− Φ
®
c− (w1)1/2Φ−1(t1)
(1− w1)1/2
´ô
dt1
å/
Φ
{
Φ−1(t3) + c′
}
dt3
By the Leibniz Rule, one could verify that dQ(w1)/dw1 ≤ 0 for w1 ∈ (0, 1), and therefore
Q(w1) is a decreasing function with respect to w1.
2 Proof for Theorem 3
Theorem 3. With a normal response and three active treatment groups, we have
prH0
¶
S
Ä
N12 , N
1
2
ä
> c
© ≤ α.
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Proof. By writing pr {S (N12 , N12 ) > c} as
pr
ï¶
w1(β1n
0
2)
©1/2
Z1 +
¶
1− w1(β1n02)
©1/2
Z2 > c|Z1 ≥ max(Z21 + c′, Z31 + c†)
ò
×
pr
î
Z1 ≥ max(Z21 + c′, Z31 + c†)
ó
+
pr
ï¶
w1(β2n
0
2)
©1/2
Z1 +
¶
1− w1(β2n02)
©1/2
Z2 > c|max(Z21 + c′, Z31 + c†) > Z1 ≥ min(Z21 + c′, Z31 + c†)
ò
×
pr
î
max(Z21 + c
′, Z31 + c
†) > Z1 ≥ min(Z21 + c′, Z31 + c†)
ó
+
pr
ï¶
w1(β3n
0
2)
©1/2
Z1 +
¶
1− w1(β3n02)
©1/2
Z2 > c|Z1 < min(Z21 + c′, Z31 + c†)
ò
×
pr
î
Z1 < min(Z
2
1 + c
′, Z31 + c
†)
ó
, (14)
where Z31 = (n
3
1)
1/2
(X
3
1−µ0), c† = (n31)1/2 µ0−(n11)1/2 µ0, one could show that the first and the
third components in (14) are not larger than their counterparts in pr {S (N12 , β2n02) > c}, while the
second terms are equal. Since pr {S (N12 , β2n02) > c} = α, then pr {S (N12 , N12 ) > c} ≤ α.
3 Asymptotic type I error rate of pairwise comparison for a
binary endpoint
In this section, we generalize Theorem 1 and 2 in the article for a continuous endpoint to prove the
asymptotic type I error protection of using the proportional test for a binary data. The asymptotic
argument is due to the normal approximation of the binary endpoint.
Consider a binary endpoint Rg following a binomial distribution:
Rg ∼ Binomial(ng, pg), (15)
with size ng and rate pg in group g, for g = 0, 1, 2. Again we consider the comparison between
27
low dose group g = 1 versus placebo g = 0. To test H0 : p1 ≤ p0 against H1 : p1 > p0 in a
non-adaptive design, one could use the one-sided version of the Pearson Chi-squared test (i.e.,
the proportional test):
P = sign
Ç
R1
n1
− R
0
n0
åÑ 1∑
g=0
[
(Rg − p̂ng)2
p̂ng
+
{ng −Rg − (1− p̂)ng}2
(1− p̂)ng
]é1/2
, (16)
where p̂ = (R1 +R0)/(n1 + n0) under H0. One could further simplify (16) as
P =
Ç
R1
n1
− R
0
n0
å/®
p̂(1− p̂)
Ç
1
n11
+
1
n0
å´1/2
. (17)
As an analogy to the formulation of S (N12 , N
1
2 ) with a continuous endpoint, the statistics in (17)
could be written as P (N12 , N
1
2 ), where
P (a, b) = {w1(b)}1/2 T1 + {1− w1(b)}1/2 T2(a),
and where
T1 =
Ä
n11
ä1/2 ÇR11
n11
− p1
å/
{p̂(1− p̂)}1/2,
T2(a) =
®
a
n11 + a
Ç
R12
n12
− p1
å
−
Ç
R0
n0
− p0
å´/ñ®
a
(n11 + a)
2
+
1
n0
´
{p̂(1− p̂)}
ô1/2
.
Theorem 4. In our proposed design with a binary response in (15) and two or three active
treatment groups, we have
pr
¶
P
Ä
N12 , N
1
2
ä
> c
© ≤ α +O(n˜−1/2),
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where n˜ = min (n11, n
1
2, n
0).
The proof follows the corresponding one with a continuous endpoint along with the strong
consistency of p̂ to p1 = p0 under H0. Note that the asymptotic error term comes from the
convergence rate of the Central Limit Theorem in the context of a binary endpoint quantified by
the Berry-Esseen Theorem.
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Table 1: Type I error rate of RABR design with a continuous endpoint
n µg = µ0 r Probability of rejecting null hypothesis
for g = 0, 1, 2, 3 with no multiplicity adjustment with step-down Dunnett
D1 D2 D3 D1 D2 D3 overall
120 0 8, 4, 4, 4 2.57% 2.46% 2.42% 1.02% 0.97% 0.91% 2.48%
8, 5, 4, 3 2.41% 2.41% 2.44% 0.95% 0.94% 0.93% 2.45%
8, 7, 4, 1 2.20% 2.15% 2.24% 0.82% 0.84% 0.85% 2.23%
8, 5, 5, 2 2.46% 2.35% 2.45% 0.95% 0.92% 0.96% 2.45%
9, 9, 1, 1 1.91% 1.99% 1.85% 0.75% 0.78% 0.69% 2.08%
1 8, 4, 4, 4 2.49% 2.47% 2.52% 1.01% 1.00% 0.99% 2.54%
8, 5, 4, 3 2.46% 2.40% 2.35% 0.95% 0.92% 0.89% 2.41%
8, 7, 4, 1 2.23% 2.18% 2.24% 0.85% 0.87% 0.83% 2.24%
8, 5, 5, 2 2.46% 2.42% 2.43% 0.98% 0.98% 0.98% 2.54%
9, 9, 1, 1 1.92% 1.96% 1.92% 0.72% 0.75% 0.71% 2.05%
40 0 8, 4, 4, 4 2.49% 2.49% 2.52% 0.99% 1.01% 1.02% 2.53%
8, 5, 4, 3 2.31% 2.29% 2.33% 0.91% 0.90% 0.93% 2.34%
8, 7, 4, 1 2.25% 2.25% 2.21% 0.89% 0.87% 0.88% 2.32%
8, 5, 5, 2 2.41% 2.41% 2.39% 0.97% 0.97% 0.97% 2.50%
9, 9, 1, 1 1.92% 1.90% 1.89% 0.74% 0.70% 0.72% 1.98%
1 8, 4, 4, 4 2.59% 2.54% 2.53% 1.01% 1.02% 0.99% 2.58%
8, 5, 4, 3 2.44% 2.42% 2.46% 0.94% 0.93% 0.99% 2.43%
8, 7, 4, 1 2.21% 2.24% 2.17% 0.86% 0.85% 0.87% 2.27%
8, 5, 5, 2 2.41% 2.36% 2.43% 0.95% 0.92% 0.92% 2.38%
9, 9, 1, 1 1.96% 1.89% 1.94% 0.72% 0.73% 0.73% 2.00%
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Table 2: Power for selected treatment groups in RABR, fixed randomization design and DBCD
µ Method η Step-down Dunnett adjusted power
of selecting and confirming the efficacy in
D1 D2 D3 overall
µA RABR - 0.98% 12.39% 70.26% 83.63%
Fixed - 0.69% 9.57% 65.35% 75.61%
DBCD -2 0.64% 9.70% 65.67% 76.00%
0 0.68% 9.16% 66.11% 75.94%
2 0.42% 7.74% 66.75% 74.90%
µB RABR - 11.76% 33.46% 45.28% 90.50%
Fixed - 9.62% 31.38% 44.28% 85.29%
DBCD -2 9.46% 31.61% 44.33% 85.39%
0 9.34% 31.75% 43.91% 84.99%
2 8.38% 29.97% 43.55% 81.91%
µC RABR - 10.14% 40.57% 41.15% 91.86%
Fixed - 8.33% 39.40% 39.51% 87.24%
DBCD -2 8.39% 39.62% 39.56% 87.57%
0 8.06% 39.37% 39.37% 86.80%
2 6.88% 38.63% 38.47% 83.98%
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Table 3: Average sample size for selected treatment groups in RABR, fixed randomization design
and DBCD
µ Method η Average sample size
placebo S1 S2 S3
Target sample size: 42 42 18 18
µA RABR - 42.00 40.55 19.27 18.18
Fixed - 30.00 30.15 29.96 29.89
DBCD -2 29.95 30.10 30.02 29.94
0 27.98 31.90 30.75 29.37
2 22.57 38.96 32.13 26.34
µB RABR - 42.00 40.23 19.55 18.22
Fixed - 29.98 30.34 30.03 29.65
DBCD -2 29.92 30.16 30.05 29.88
0 27.47 31.54 30.91 30.07
2 21.02 36.72 33.07 29.19
µC RABR - 42.01 40.31 19.48 18.20
Fixed - 29.99 30.34 30.00 29.67
DBCD -2 29.93 30.16 30.03 29.88
0 27.45 31.55 30.91 30.09
2 20.90 36.83 33.18 29.10
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Table 4: Power and operating characteristics in RABR, non-adaptive design, and DBCD
Method Bonferroni adjusted power Average sample size
of selecting and confirming
D1 D2 overall Placebo S1 S2
RABR 6.99% 74.59% 81.58% 72.02 70.15 37.84
Fixed randomization 5.10% 70.99% 76.09% 59.98 60.10 59.91
DBCD 4.16% 70.89% 75.06% 50.30 67.68 62.02
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